UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 Delaware 27-1537290 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 100 ...

WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 - 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). "The 11 oral presentations ...

Apellis Pharmaceuticals Inc (NASDAQ: APLS) is down nearly 40% versus its year-to-date high but a Mizuho analyst does not see it as an opportunity to buy per se.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Mizuho remains ‘neutral’ on Apellis Pharmaceuticals stockCopy link to sectionGraig Suvannavejh reiterated his “neutral” stance on the biotech stock in a recent research note.  While his $52 price target does suggest meaningful upside from here – a ...

Apellis Pharmaceuticals, Inc. (APLS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be relea ...

Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA's expert groupsApellis anticipates a CHMP opinion no later than July 2024 WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the European Medicines Agency (EMA) has reset the review of the marketing authorization application (MAA) for intravitreal pegcetacoplan for geographic atrophy to the last phase of the initial assessmen ...

Apellis Pharmaceuticals, Inc. (APLS) reported fourth-quarter 2023 loss of 73 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 66 cents. The company had reported a loss of $1.50 per share in the year-ago quarter.Total revenues amounted to $146.4 million in the fourth quarter, matching the Zacks Consensus Estimate. In the year-ago quarter, the company had reported revenues of $22.6 million.The top line jumped almost 545% year over year owing to higher sales of Syfovre (pegcetaco ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 Full Year 2023 Earnings Conference Call February 27, 2024 8:30 AM ET Company Participants Cedric Francois - Co-Founder and Chief Executive Officer Tim Sullivan - Chief Financial Officer Adam Townsend - Chief Operating Officer Caroline Baumal - Chief Medical Officer Meredith Kaya - SVP of Investor Relations and Strategic Finance Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - J.P. Morgan Yigal Nochomovitz - C ...

Apellis Pharmaceuticals, Inc. (APLS) reported $146.38 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 546%. EPS of -$0.73 for the same period compares to -$1.50 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $146.43 million, representing a surprise of -0.03%. The company delivered an EPS surprise of -10.61%, with the consensus EPS estimate being -$0.66.While investors closely watch year-over-year changes in headline numbers -- re ...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $1.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.61%. A quarter ago, it was expected that this company would post a loss of $0.84 per share when it actually produced a loss of $1.17, delivering a surprise of -39.29%.Over the last four quarters, the comp ...

Fourth Quarter and Full Year 2023 Financial Results Conference Call Apellis Participants CEDRI C F RANCO I S, M. D. , Ph . D. Co-Founder, President & Chief Executive Officer ...